The study also found that the effectiveness of the Pfizer and Moderna vaccines was only 29% during the omicron BA.4 and BA.5 variant phases, 20% during the BQ-dominant phase, and 4% during the XBB-dominant phase.
Under-reporting of injuries following vaccination "should be considered when delivering information to the community and in public health decision-making," the study authors write.
The FDA has "repeatedly stated that effectiveness against transmission remains unproven," the trio write, noting that the agency’s website maintains: "the scientific community does not yet know if Comirnaty will reduce such transmission."
"The conventional SARS-CoV-2 vaccine’s ability to provide immunological protection may be significantly impacted by over-vaccination. If this happens, either newly diagnosed COVID-19 cases or people who have already contracted the virus again may have a more severe case of the illness. This concept was proposed after seeing tolerance of both the humoral and cellular immune responses to prolonged booster immunization doses."
"The signal detected for myocarditis or pericarditis is consistent with that reported in peer-reviewed publications demonstrating an elevated risk of myocarditis or pericarditis following mRNA vaccines, especially among younger males aged 12 to 29 years," the researchers noted.
